NEURANA PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2013-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.neuranapharma.com
Clinical Trials
5
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of Tolperisone in Subjects With Pain Due to Acute Back Muscle Spasm
- Conditions
- Back Muscle SpasmBack Spasm UpperBack StrainBack PainMuscle SpasmAcute Pain
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Neurana Pharmaceuticals, Inc.
- Target Recruit Count
- 1004
- Registration Number
- NCT04671082
- Locations
- 🇺🇸
Clinical Research Institute of Arizona, LLC, Surprise, Arizona, United States
🇺🇸Applied Research Center of Arkansas, Little Rock, Arkansas, United States
🇺🇸Alliance Research Institute, Canoga Park, California, United States
A Phase 1 PK Study of Tolperisone in Healthy Subjects
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- Neurana Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04465266
- Locations
- 🇺🇸
Worldwide Clinical Trials Early Phase Services, LLC, San Antonio, Texas, United States
Effects of Tolperisone on Measures of Drowsiness and Cognitive Function
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- Neurana Pharmaceuticals, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT04407377
- Locations
- 🇺🇸
CNS Trial, Long Beach, California, United States
🇺🇸Hassman Research Institute, Berlin, New Jersey, United States
Tolperisone in Acute Muscle Spasm of the Back
- Conditions
- Acute PainMuscle SpasmLow Back PainBack Spasm Upper BackBack StrainMuscle CrampBack Pain
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- Neurana Pharmaceuticals, Inc.
- Target Recruit Count
- 415
- Registration Number
- NCT03802565
- Locations
- 🇺🇸
Tennessee Valley Pain Consultants, Huntsville, Alabama, United States
🇺🇸Fiel Family and Sports Medicine, Tempe, Arizona, United States
🇺🇸Center of Applied Research, Little Rock, Arkansas, United States
Driving Simulation to Assess Non-Sedative Effects of Tolperisone
- Conditions
- Driving Impaired
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2017-11-27
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- Neurana Pharmaceuticals, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT03353922
- Locations
- 🇺🇸
Collaborative Neuroscience Network, Long Beach, California, United States
🇺🇸NeuroTrials Research, Atlanta, Georgia, United States